Treatment of myelofibrosis and primary erythermalgia
✍ Scribed by Şinasi Özsoylu
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 246 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Myelofibrosis may be classified as ''primary'' or as secondary. Secondary myelofibrosis represents the reaction of the bone marrow stroma to a non-hemopoietic condition, such as metastatic carcinoma. Myelofibrosis that is classified as ''idiopathic'' or ''primary'' is a myeloproliferative disorder i
## Abstract Idiopathic myelofibrosis (IMF) is the least common of the chronic myeloproliferative disorders and carries the worst prognosis with a median survival of 4 years. It is a clonal haematopoietic stem‐cell disorder and, although the pathogenesis remains unclear, approximately 50% of cases a